Things appear to be going from bad to worse at Teva, which is giving the strong impression of being in meltdown. One can only hope that the recent Q2 results, which featured an eye-watering $6.1bn write-down of the company’s recently-acquired Actavis generics assets, mark...
Biosimilars: The five stages of grief
According to the Swiss psychiatrist Elisabeth Kübler-Ross, grief has five stages: denial, anger, bargaining, depression and acceptance. Although the development of biosimilars should not be an inherently grief-stricken business, it nevertheless appears to be closely following this path, certainly from the perspective of the...
Unfair! DoH temper tantrum is no help to generic drug pricing policy in the UK
The UK generics industry has been waiting for over a year to find out what the CMA’s final decision would be on the Pfizer/Flynn phenytoin case, following its preliminary ruling in August 2015 that the two companies were guilty of abuse of a dominant...